
Makes every class a memorable experience.
Encourages deep understanding and curiosity.
Inspires a passion for knowledge and growth.
Brings real-world examples to learning.
Encourages deep understanding and curiosity.
Edward Giles, MBBS, PhD, FRACP, is an Adjunct Associate Professor in the Department of Paediatrics, School of Clinical Sciences at Monash Health, Monash University. As a consultant Paediatric Gastroenterologist and Lead for Inflammatory Bowel Disease at Monash Children’s Hospital, he bridges clinical practice and research. His academic journey includes an MBBS from the University of Melbourne (2000), MRCPCH (2004), PhD from the University of London (2015) on type I interferon signaling in human intestinal T cells, and FRACP (2016). Trained at the Royal Children’s Hospital Melbourne and London hospitals, he served as Consultant and Lecturer at the Royal London Hospital and Barts Medical School until early 2016. Since February 2016, he has been at Monash Health, and holds appointments as Research Fellow and Senior Research Scientist at the Hudson Institute of Medical Research’s Centre for Innate Immunity and Infectious Diseases.
Giles specializes in host-microbiome interactions, mucosal immunology, and novel biotherapeutics for paediatric IBD. His projects include bacterial therapeutics, organoid models, coeliac disease, and interferon roles in gut inflammation. He leads a pioneering IBD transition clinic and contributes to Australia’s largest adult IBD clinical trials unit. Awards include the Barry Marshall Mid-Career Award (2025) for microbiome research in IBD and the Kenneth Rainin Foundation Innovator Award (2019, US$175,000) for therapeutic bacteria. Key publications: “A widespread hydrogenase supports fermentative growth of gut bacteria in healthy people” (Nature Microbiology, 2025); “Pediatric to Adult Transition in Inflammatory Bowel Disease: Consensus Guidelines for Australia and New Zealand” (Inflammatory Bowel Diseases, 2025); “Epithelially Restricted Interferon Epsilon Protects Against Colitis” (Cellular and Molecular Gastroenterology and Hepatology, 2024); “Regulation of human intestinal T-cell responses by Type 1 Interferon-STAT1 signalling is disrupted in inflammatory bowel disease” (Mucosal Immunology, 2017). He leads as President of the Australian Society of Paediatric Gastroenterology, Hepatology and Nutrition, Chair of the GESA Paediatric Network, and GESA research committee member.